GMED Quote, Financials, Valuation and Earnings

Boston Scientific Corp. has a net margin of 15.47% compared to Globus Medical, Inc.'s net margin of 14.91%. Globus Medical, Inc.'s return on equity of 10.08% beat Boston Scientific Corp.'s return on equity of 12.46%.

Globus Medical, Inc. has a consensus price target of $106.73, signalling upside risk potential of 16.22%. On the other hand Boston Scientific Corp. has an analysts' consensus of $124.41 which suggests that it could grow by 32.64%. Given that Boston Scientific Corp. has higher upside potential than Globus Medical, Inc., analysts believe Boston Scientific Corp. is more attractive than Globus Medical, Inc..

Globus Medical, Inc. has a beta of 1.064, which suggesting that the stock is 6.426% more volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.670, suggesting its less volatile than the S&P 500 by 33.029%.

Globus Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Globus Medical, Inc. pays -- of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend.

Globus Medical, Inc. quarterly revenues are $769M, which are smaller than Boston Scientific Corp. quarterly revenues of $5.1B. Globus Medical, Inc.'s net income of $119M is lower than Boston Scientific Corp.'s net income of $755M. Notably, Globus Medical, Inc.'s price-to-earnings ratio is 29.68x while Boston Scientific Corp.'s PE ratio is 50.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Globus Medical, Inc. is 4.57x versus 7.24x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical, Inc. has a net margin of 15.47% compared to Globus Medical, Inc.'s net margin of 27.89%. Globus Medical, Inc.'s return on equity of 10.08% beat Intuitive Surgical, Inc.'s return on equity of 16.59%.

Globus Medical, Inc. has a consensus price target of $106.73, signalling upside risk potential of 16.22%. On the other hand Intuitive Surgical, Inc. has an analysts' consensus of $611.82 which suggests that it could grow by 17.2%. Given that Intuitive Surgical, Inc. has higher upside potential than Globus Medical, Inc., analysts believe Intuitive Surgical, Inc. is more attractive than Globus Medical, Inc..

Globus Medical, Inc. has a beta of 1.064, which suggesting that the stock is 6.426% more volatile than S&P 500. In comparison Intuitive Surgical, Inc. has a beta of 1.669, suggesting its more volatile than the S&P 500 by 66.867%.

Globus Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intuitive Surgical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Globus Medical, Inc. pays -- of its earnings as a dividend. Intuitive Surgical, Inc. pays out -- of its earnings as a dividend.

Globus Medical, Inc. quarterly revenues are $769M, which are smaller than Intuitive Surgical, Inc. quarterly revenues of $2.9B. Globus Medical, Inc.'s net income of $119M is lower than Intuitive Surgical, Inc.'s net income of $799.5M. Notably, Globus Medical, Inc.'s price-to-earnings ratio is 29.68x while Intuitive Surgical, Inc.'s PE ratio is 66.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Globus Medical, Inc. is 4.57x versus 18.81x for Intuitive Surgical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Insulet Corp. has a net margin of 15.47% compared to Globus Medical, Inc.'s net margin of 12.4%. Globus Medical, Inc.'s return on equity of 10.08% beat Insulet Corp.'s return on equity of 18.92%.

Globus Medical, Inc. has a consensus price target of $106.73, signalling upside risk potential of 16.22%. On the other hand Insulet Corp. has an analysts' consensus of $370.44 which suggests that it could grow by 43.47%. Given that Insulet Corp. has higher upside potential than Globus Medical, Inc., analysts believe Insulet Corp. is more attractive than Globus Medical, Inc..

Globus Medical, Inc. has a beta of 1.064, which suggesting that the stock is 6.426% more volatile than S&P 500. In comparison Insulet Corp. has a beta of 1.400, suggesting its more volatile than the S&P 500 by 39.975%.

Globus Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Globus Medical, Inc. pays -- of its earnings as a dividend. Insulet Corp. pays out -- of its earnings as a dividend.

Globus Medical, Inc. quarterly revenues are $769M, which are larger than Insulet Corp. quarterly revenues of $706.3M. Globus Medical, Inc.'s net income of $119M is higher than Insulet Corp.'s net income of $87.6M. Notably, Globus Medical, Inc.'s price-to-earnings ratio is 29.68x while Insulet Corp.'s PE ratio is 74.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Globus Medical, Inc. is 4.57x versus 7.41x for Insulet Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Stryker Corp. has a net margin of 15.47% compared to Globus Medical, Inc.'s net margin of 14.18%. Globus Medical, Inc.'s return on equity of 10.08% beat Stryker Corp.'s return on equity of 14.06%.

Globus Medical, Inc. has a consensus price target of $106.73, signalling upside risk potential of 16.22%. On the other hand Stryker Corp. has an analysts' consensus of $425.68 which suggests that it could grow by 18.96%. Given that Stryker Corp. has higher upside potential than Globus Medical, Inc., analysts believe Stryker Corp. is more attractive than Globus Medical, Inc..

Globus Medical, Inc. has a beta of 1.064, which suggesting that the stock is 6.426% more volatile than S&P 500. In comparison Stryker Corp. has a beta of 0.890, suggesting its less volatile than the S&P 500 by 10.974%.

Globus Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stryker Corp. offers a yield of 0.95% to investors and pays a quarterly dividend of $0.88 per share. Globus Medical, Inc. pays -- of its earnings as a dividend. Stryker Corp. pays out 41.74% of its earnings as a dividend. Stryker Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Globus Medical, Inc. quarterly revenues are $769M, which are smaller than Stryker Corp. quarterly revenues of $6.1B. Globus Medical, Inc.'s net income of $119M is lower than Stryker Corp.'s net income of $859M. Notably, Globus Medical, Inc.'s price-to-earnings ratio is 29.68x while Stryker Corp.'s PE ratio is 46.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Globus Medical, Inc. is 4.57x versus 5.67x for Stryker Corp.. Usually stocks with elevated PS ratios are considered overvalued.